Steroid withdrawal in renal transplant patients on triple therapy with a calcineurin inhibitor and mycophenolate mofetil: A meta-analysis of randomized, controlled trials

Transplantation

Volumn 78, Issue 10, 2004, Pages 1548-1556

  Pascual, Julio ^a   Quereda, Carlos ^a   Zamora, Javier ^a   Hernández, Domingo ^b  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

Author keywords

Cyclosporine; Meta analysis; Renal transplantation; Steroid withdrawal; Tacrolimus

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; STEROID; TACROLIMUS;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG WITHDRAWAL; FOLLOW UP; GRAFT FAILURE; HUMAN; KIDNEY ALLOGRAFT REJECTION; KIDNEY GRAFT; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

ADRENAL CORTEX HORMONES; CALCINEURIN; CYCLOSPORINE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; RANDOMIZED CONTROLLED TRIALS; TACROLIMUS;

EID: 9244234438     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000140969.43761.1F     Document Type: Article

References (51)

1. Veenstra DL, Best JH, Homberger J, et al. The incidence and long-term cost of steroid-related effects after renal transplantation. Am J Kidney Dis 1999; 33: 829.
2. Hricik DE, O'Toole MA, Schulak JA, et al. Steroid-free immunosuppression in cyclosporine-treated renal transplant recipients: A meta-analysis. J Am Soc Nephrol 1993; 4: 1300.
3. Kasiske BL, Chakkera HA, Louis TA, et al. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 2000; 11: 1910.
4. Isoniemi HM, Ahonen J, Tikkanen MJ, et al. Long-term consequences of different immunosuppressive regimens for renal allografts. Transplantation 1993; 55: 494.
5. Maiorca R, Cristinelli L, Brunori G, et al. Prospective controlled trial of steroid withdrawal after six months in renal transplant recipients treated with cyclosporine. Transplant Proc 1988; 20: 121.
6. Schulak JA, Mayes JT, Moritz CE, et al. A prospective, randomized trial of prednisone versus no prednisone maintenance therapy in cyclosporine-treated and azathioprine-treated renal transplant patients. Transplantation 1990; 49: 327.
7. Hollander AA, Hene RJ, Hermans J, et al. Late prednisone withdrawal in cyclosporine-treated kidney transplant recipients: A randomized study. J Am Soc Nephrol 1997; 8: 294.
8. Gulanikar AC, Belitsky P, MacDonald AS, et al. Randomized controlled trial of steroids versus no steroids in stable cyclosporine-treated renal graft recipients. Transplant Proc 1991; 23: 990.
9. Ratcliffe PJ, Dudley CR, Higgins RM, et al. Randomized controlled trial of steroid withdrawal in renal transplant patients receiving triple immunosuppression. Lancet 1996; 348: 643.
10. Ponticelli C, Tarantino A, Segoloni GP, et al. A randomized study comparing three cyclosporine-based regimens in cadaveric renal transplantation. J Am Soc Nephrol 1997; 8: 638.
11. Sinclair NR. Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts: The Canadian Multicentre Transplant Study Group. Can Med Assoc J 1992; 147: 645.
12. Margreiter R. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: A randomized multicentre study. European Tacrolimus vs Ciclosporin-Microemulsion Renal Transplantation Study Group. Lancet 2002; 359: 741.
13. Halloran P, Matthew S, Tomlanovich S, et al. Mycophenolate mofetil in renal allograft recipients: A pooled efficacy analysis of three randomized, double-blind, clinical studies in the prevention of rejection. International Mycophenolate Mofetil Renal Transplant Study Group. Transplantation 1997; 63: 39.
14. Review Manager (RevMan) [Computer program]. Version 4.2 for Windows. Oxford, England: The Cochrane Collaboration, 2003.
15. Ashan N, Hricik D, Matas A, et al. Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil: A prospective, randomized study. Transplantation 1999; 68: 1865.
16. Vanrenterghem Y, Lebranchu Y, Hene R, et al. Double-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection: Steroid Dosing Study Group. Transplantation 2000; 70: 1352.
17. Smak Gregoor PJH, De Sevaux RGL, Ligtenberg G, et al. Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy. A randomized, prospective, multicenter study. J Am Soc Nephrol 2002; 13: 1365.
18. Boletis JN, Konstadinidou I, Chelioti H, et al. Successful withdrawal of steroid after renal transplantation. Transplant Proc 2001; 33: 1231.
19. Squifflet JP, Vanrenterghem Y, Van Hooff JP, et al. Safe withdrawal of corticosteroids or mycophenolate mofetil: Results of a large, prospective, multicenter, randomized study. European Tacrolimus/MMF Transplantation Study Group. Transplant Proc 2002; 34: 1584.
20. Sola E, Alferez MJ, Cabello M, et al. Low-dose and rapid steroid withdrawal in renal transplant patients treated with tacrolimus and mycophenolate mofetil. Transplant Proc 2002; 34: 1689.
21. Lebranchu Y. Comparison of two corticosteroid regimens in combination with CellCept and cyclosporine A for prevention of acute allograft rejection: 12 month results of a double-blind, randomized, multi-center study. M 55002 Study Group. Transplant Proc 1999; 31: 249.
22. Grinyo JM, Gil-Vernet S, Seron D. Steroid withdrawal in mycophenolate mofetil-treated renal allograft recipients. Transplantation 1997; 63: 1688.
23. Birkeland SA. Steroid-free immunosuppression after kidney with anti-thymocyte globulin induction and cyclosporine and mycophenolate mofetil maintenance therapy. Transplantation 1998; 66: 1207.
24. Bertoni E, Zanazzi M, Rosati A, et al. Long-term steroid side effects in renal transplantation need a safe steroid withdrawal: A single-center experience. Transplant Proc 1998; 30: 1303.
25. Woodle ES, Buell J, Siegel C, et al. Corticosteroid withdrawal under tacrolimus primary and rescue therapy in renal transplantation: The Chicago experience. Transplant Proc 1999; 31: 84S.
26. Puig i Mari JM. Induction treatment with mycophenolate mofetil, cyclosporine, and low-dose steroids with subsequent early withdrawal in renal transplant patients: Results of the Spanish Group. Spanish Group of the CellCept Study. Transplant Proc 1999; 31: 2256.
27. Gregoor PJ, de Sevaux RGL, Hene RJ, et al. Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients. Transplantation 1999; 68: 1603.
28. Lebranchu Y, Aubert P, Bayle F, et al. Could steroids be withdrawn in renal transplant patients sequentially treated with ATG, cyclosporine, and cellcept? One-year results of a double-blind, randomized, multicenter study comparing normal dose versus low-dose and withdrawal of steroids. M 55002 French Study Group. Transplant Proc 2000; 32: 396.
29. Kupin W, Venkat KK, Goggins M, et al. Improved outcome of steroid withdrawal in mycophenolate mofetil-treated primary cadaveric renal transplant recipients. Transplant Proc 2001; 31: 1131.
30. Budde K, Pritsche L, Geissler S, et al. Steroid withdrawal in long-term cyclosporine A treated patients using mycophenolate mofetil: A prospective randomized pilot study. Transplant Proc 2001; 33: 3250.
31. Vincenti F, Monaco A, Grinyo J, et al. Rapid steroid withdrawal versus standard steroid therapy in patients treated with basiliximab, cyclosporine, and mycophenolate mofetil for the prevention of acute rejection in renal transplantation. Transplant Proc 2001; 33: 1011.
32. Birkeland SA. Steroid-free immunosuppression in renal transplantation: A long-term follow-up of 100 consecutive patients. Transplantation 2001; 71: 1089.
33. Mahalati K, Kahan BD. A pilot study of steroid withdrawal from kidney transplant recipients on sirolimus-cyclosporine a combination therapy. Transplant Proc 2001; 33: 3232.
34. Hricik DE. Steroid withdrawal in renal transplantation. Transplant Proc 2001; 33: 3261.
35. Mahalati K, Kahan BD. Sirolimus permits steroid withdrawal from a cyclosporine regimen. Transplant Proc 2001; 33: 1270.
36. Chakrabati P, Wong HY, Toyofuku A, et al. Outcome after steroid withdrawal in adult renal transplant patients receiving tacrolimus-based immunosuppression. Transplant Proc 2001; 33: 1235.
37. Gomez E, Laures A, Pobes A, et al. Steroid withdrawal in renal transplantation treated with cyclosporine A: Long-term evolution. Transplant Proc 2001; 33: 3263.
38. Budde K, Geissler S, Hallebach G, et al. Prospective randomized pilot study of steroid withdrawal with mycophenolate mofetil in long-term cyclosporine-treated patients: 4-year follow-up. Transplant Proc 2002; 34: 1703.
39. Boots JMM, Christians MHL, Van Duijnhoven EM, et al. Early steroid withdrawal in renal transplantation with tacrolimus dual therapy: A pilot study. Transplantation 2002; 74: 1703.
40. Alarcón-Zurita A, Munar MA, Losada P, et al. Steroids withdrawal after 3 months of successful renal transplantation using a tacrolimus- and mycophenolate-based immunosuppression. Transplant Proc 2002; 34: 118.
41. Beaunoyer M, Busque S, St-Louis G, et al. Low-dose tacrolimus, trough-monitored mycophenolate mofetil and planned steroid withdrawal for cadaveric kidney transplantation: A single center experience. Transplant Proc 2002; 34: 1694.
42. Citterio F, Rigotti P, Scata MC, et al. Steroid withdrawal from tacrolimus-based therapy in renal transplant patients. Transplant Proc 2002; 34: 1707.
43. Hricik D, Knauss TC, Bodziak KA, et al. Withdrawal of steroid therapy in African American kidney transplant recipients treated with sirolimus and tacrolimus. Transplantation 2002; 76: 938.
44. Sandrini S, Rizzo G, Valente U, et al. Basiliximab facilitates steroid withdrawal after renal transplantation. Results of an Italian multicentre, placebo-controlled study (Swiss Study) [abstract]. Am J Transplant 2002; 2(suppl): 172.
45. Francos CG, Frankel CJ, Dunn SR, et al. Double-blind, placebo controlled, 3-year study of steroid withdrawal using a neoral and mycophenolate mofetil-based immunosuppressive regimen in primary renal transplants patients [abstract]. Am J Transplant 2002; 2(suppl): 172.
46. Kumar MSA, Fa K, Fyfe B, et al. Steroid avoidance in kidney transplant recipients treated with Simulect, Neoral CsA and CellCept: A randomized, prospective controlled clinical trial [abstract]. Am J Transplant 2002; 2(suppl): 393.
47. Maes BD, Kuypers D, Evenpoel P, et al. Effects of cessation of steroids on renal function and cardiovascular profile in renal transplant recipients [abstract]. Am J Transplant 2002; 2(suppl): 394.
48. Kim EH, Yango A, Morrissey P, et al. Rapid steroid withdrawal versus standard steroid treatment in patients treated with basiliximab, cyclosporine, mycophenolate mofetil for the prevention of acute rejection in kidney transplantation: A 2 year follow-up [abstract]. Am J Transplant 2002; 2(suppl): 397.
49. Matas AJ, Gillingham KJ, Payne WD, et al. The impact of an acute rejection on long-term renal allograft survival. Transplantation 1994; 57: 857.
50. Vereerstraeten P, Abramowicz D, De Pauw L, et al. Absence of deleterious effect on long-term kidney graft survival of rejection episodes with complete functional recovery. Transplantation 1997; 63: 1739.
51. Van Hooff JP, Salmela K, Budde K, et al. Long-term efficacy and safety of steroid-withdrawal in tacrolimus-treated patients: Results of a long-term follow-up study in renal transplant recipients. European Society for Organ Transplantation, Venice, Italy, September 20-24, 2003. Abstract Book, p. 45.